查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1867274

鴉片類藥物市場按鴉片類藥物類型、給藥途徑、用途和最終用戶分類－2025年至2032年全球預測

Opioids Market by Opioid Types, Mode of Administration, Application, End-User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，鴉片類藥物市場規模將成長至 299.6 億美元，年複合成長率為 4.21%。

關鍵市場統計數據
基準年 2024 215.3億美元
預計年份：2025年 224.4億美元
預測年份 2032 299.6億美元
複合年成長率 (%) 4.21%

對鴉片類藥物治療現況的簡要概述，闡述臨床需求、監管壓力和決策者的策略重點。

在治療需求、安全問題和不斷演變的法規結構交織的複雜背景下，鴉片類藥物治療領域持續受到臨床、監管和政策相關人員的密切關注。本導言闡述了本報告所採用的分析觀點，將鴉片類藥物置於現代治療路徑中，同時強調需要在有效緩解疼痛和麻醉的同時，加強對濫用和不良後果的防範。透過整合臨床實務趨勢、監管發展和供應鏈現狀，本報告重點闡述了藥物研發人員、醫療保健提供者和公共衛生組織面臨的關鍵挑戰和機會。

不斷發展的臨床實踐、法律規範和劑量創新如何重塑醫療保健機構中鴉片類藥物治療的開發和管理

鴉片類藥物治療領域正經歷變革性的轉變，臨床實務、產品研發和監管都在重塑。合成鴉片類藥物化學的進步，加上監管力度的加強和處方控制的日益嚴格，正在推動控釋劑型的重新研發和濫用抑制技術的探索。同時，給藥系統的創新，例如改良的經皮基質和定向注射製劑，正在重新定義各種醫療機構中鎮痛和麻醉的給藥方式。

評估2025年貿易關稅調整對鴉片類藥物供應鏈、採購經濟及臨床取得策略的累積影響

2025年美國關稅對鴉片類藥物供應鏈產生了累積影響，波及原料採購、生產物流和臨床採購等各環節。某些前驅物和成品藥進口關稅的提高，迫使製造商重新審視投入成本，並重新評估其供應商組合和合約條款。為此，許多相關人員加快了多元化策略的實施，優先考慮本地採購，並對替代供應商進行資格審核，以降低關稅帶來的成本上行風險。

透過多維細分分析，突顯治療類別、給藥途徑、臨床應用和最終用戶部署的影響，可以幫助制定策略。

精細化的細分框架能夠辨識治療研發和臨床應用的分歧與融合領域，為策略優先排序提供切實可行的觀點。以鴉片類藥物類型進行分析，突顯了天然鴉片類藥物（如可待因和氫可酮）、半合成藥物（如氫可酮和羥考酮）以及全合成化合物（包括Fentanyl和美沙酮）之間的差異。每類藥物都具有獨特的藥理學特性、監管控制和臨床應用案例，這些都會影響製劑和監測要求。

管理體制、醫療保健基礎設施和支付方優先事項的區域差異如何影響鴉片類藥物產品開發和取得的不同策略。

區域趨勢正在影響臨床實踐和商業性路徑，由此產生的顯著差異會影響優先事項的製定和執行。在美洲，臨床指引和支付方框架強調藥物管理，同時確保在急性照護環境中持續獲得必要的止痛藥物。這使得風險緩解策略和真實世界證據的收集顯得尤為重要。同時，在歐洲、中東和非洲，監管差異和不同的報銷模式導致新製劑和濫用預防技術的推廣應用曲線存在差異，因此需要針對不同區域制定市場准入和監管策略。

公司層面的策略性因應措施反映了優先事項的趨同：安全創新、一體化生產以及為維持臨床准入而產生的證據。

鴉片類藥物治療生態系統中的主要企業正在展現出多樣化的策略性應對措施，這些措施可為競爭對手和合作夥伴提供寶貴的經驗。業界領導企業正在投資製劑技術，以降低濫用風險並加強安全監測，同時擴大其無菌生產和受管制物質分銷能力。一些公司正與醫療設備製造商合作，將藥理特性與給藥方案結合，以提高劑量準確性和患者依從性。

領導者應專注於以安全為中心的創新、供應鏈韌性和協作管理，以保障准入和價值，並制定切實可行的策略重點。

產業領導者應採取一系列切實可行的措施，將洞察轉化為可捍衛的優勢，同時確保病患安全和符合監管要求。首先，應優先開發和推廣具有防濫用和安全性增強功能的製劑，並建立健全的藥物監測系統，及時產生真實世界證據，以支持臨床和支付者之間的對話。其次，應投資加強供應鏈韌性，透過供應商多元化、策略性庫存緩衝以及對區域生產合作夥伴進行合格，降低貿易和關稅波動帶來的風險。

本分析所依據的研究方法採用了一種嚴謹的混合方法，結合了證據綜合、相關人員訪談和情境分析，以得出有充分理由的策略結論和建議。

本分析的調查方法結合了對同儕審查的臨床文獻、監管申報文件和公共文件的系統性回顧，以及對臨床、生產和監管相關人員的結構化訪談。資料收集優先考慮記錄治療效果、安全性概況和政策變化的資訊來源，而綜合分析則強調跨不同證據來源的三角驗證，以增強推論的有效性。定性訪談旨在收集有關供應鏈、製劑挑戰和實施障礙的實際觀點，從而將策略主題與實際情況聯繫起來。

臨床安全、商業性韌性和協作管治這三者相互交織的迫切需求，對於維持鴉片類藥物的可及性和創新至關重要。

總之，鴉片類藥物治療領域正處於轉折點，需要各方共同努力，推動安全創新、增強供應鏈穩健性並加強跨部門合作。製劑科學和給藥技術的變革為改善治療效果提供了契機，而監管和貿易趨勢也帶來了新的限制因素，需要製定適應性強的商業和營運策略。透過將實證實踐與藥物管理計畫和健全的採購慣例結合，相關人員可以在保障臨床用藥的同時，推動公共衛生目標的實現。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 遠端醫療輔助藥物治療鴉片類藥物使用障礙的激增
  • 廣泛採用人工智慧驅動的處方藥物監測計劃，以防止處方藥濫用
  • 突破性專利到期加速非專利鴉片類止痛藥上市
  • 利用新型聚合物基質技術，擴大耐濫用配方的應用範圍
  • 透過州處方藥處方箋擴大社區藥局納洛酮的分發範圍
  • 加強支付方與醫療服務提供方在基於價值的鴉片類藥物治療合約方面的合作
  • 加強對Fentanyl和Fentanyl等非法合成鴉片類藥物類似物的監管審查
  • 過渡到其他非鴉片類鎮痛療法，包括 CGRP 和 TRPV1 抑制劑
  • 加強真實世界證據研究，以證明藥物輔助治療方案的成本效益
  • 關於鴉片類藥物訴訟和解及資金分配透明度的新法律挑戰

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 按鴉片類藥物類型分類的鴉片類藥物市場

  • 天然鴉片
    • 可待因
    • 氫可酮
  • 半合成鴉片類藥物
    • 氫可酮
    • 羥考酮
  • 合成鴉片類藥物
    • Fentanyl
    • 美沙酮

9. 依給藥途徑分類的鴉片類藥物市場

  • 口服
    • 膠囊
    • 藥片
  • 腸外給藥
    • 肌肉內注射
    • 靜脈注射
  • 經皮給藥

第10章 鴉片類藥物市場依應用領域分類

  • 麻醉
    • 全身麻醉
    • 局部麻醉
  • 抑制咳嗽
  • 疼痛管理
    • 急性疼痛
    • 慢性疼痛

第11章 以最終用戶分類的鴉片類藥物市場

  • 醫療機構
    • 診所
    • 醫院
  • 家庭醫療保健
  • 研究所

第12章：各地區的鴉片類藥物市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：按類別分類的鴉片類藥物市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國鴉片類藥物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Hikma Pharmaceuticals PLC
    • Pfizer Inc.
    • AbbVie Inc.
    • Alvogen
    • Apotex Inc.
    • Biesterfeld SE
    • Daiichi Sankyo Company, Limited
    • Elite Pharmaceuticals, Inc.
    • Endo International plc
    • Fresenius SE & Co. KGaA
    • Humanwell Healthcare（Group）Co., Ltd.
    • Indivior PLC
    • Johnson & Johnson Services, Inc.
    • Johnson Matthey Group
    • Kyowa Hakko Kirin Co. Ltd.
    • Mallinckrodt plc
    • Nutriband Inc.
    • Piramal Pharma Limited
    • Purdue Pharma LP
    • QuVa Pharma, Inc
    • SCA Pharma
    • Spectrum Chemical Mfg. Corp.
    • Teva Pharmaceutical Industries Ltd.
    • Tofigh Daru Research & Engineering Company
    • Verve HumanCare Laboratories
    • Viatris Inc.
Product Code: MRR-CB04E05659AC

The Opioids Market is projected to grow by USD 29.96 billion at a CAGR of 4.21% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 21.53 billion
Estimated Year [2025] USD 22.44 billion
Forecast Year [2032] USD 29.96 billion
CAGR (%) 4.21%

A concise orientation to the opioid therapeutics landscape framing clinical imperatives, regulatory pressure, and strategic priorities for decision-makers

The opioid therapeutics landscape continues to prompt intense scrutiny from clinical, regulatory, and policy stakeholders, driven by complex intersections of therapeutic necessity, safety concerns, and evolving regulatory frameworks. This introduction sets out the analytical lens used in the report, situating opioids within contemporary care pathways while recognizing the imperative to balance effective analgesia and anesthesia against heightened vigilance for misuse and adverse outcomes. By synthesizing clinical practice trends, regulatory signals, and supply chain realities, the report frames the primary challenges and opportunities facing pharmaceutical developers, healthcare providers, and public health agencies.

Throughout this analysis, emphasis is placed on evidence-based evaluation of therapeutic classes, routes of administration, clinical applications, and end-user dynamics. The intent is to provide decision-makers with a clear, structured understanding of where clinical demand intersects with regulatory pressures and innovation trajectories. With that orientation established, subsequent sections explore transformative shifts, policy impacts, segmentation insights, and regional dynamics, all designed to inform strategic planning, clinical protocol development, and investment prioritization.

How evolving clinical practice, regulatory oversight, and delivery innovation are reshaping opioid therapy development and stewardship across care settings

The landscape of opioid therapeutics is in the midst of transformative shifts that recalibrate clinical practice, product development, and regulatory oversight. Advances in synthetic opioid chemistry, coupled with intensified monitoring and prescription controls, have encouraged the redevelopment of controlled formulations and the exploration of abuse-deterrent technologies. At the same time, innovation in delivery systems, such as refined transdermal matrices and targeted parenteral formulations, is redefining how analgesia and anesthesia are administered across care settings.

Concurrently, payer and provider policies are shifting toward evidence-based protocols that emphasize multimodal pain management and stewardship programs designed to minimize long-term opioid exposure. These trends are accelerating the adoption of alternative pain pathways and driving more rigorous post-marketing surveillance, thereby increasing the bar for new product entry and lifecycle management. As a result, developers and clinical leaders must adapt to an environment that rewards demonstrable safety improvements, real-world outcomes data, and collaborative approaches that integrate pharmacy, surgery, and primary care perspectives.

Assessing the cumulative ramifications of 2025 trade tariff adjustments on opioid supply chains, procurement economics, and clinical access strategies

The United States tariff measures implemented in 2025 exerted a cumulative influence across the opioid supply chain, reverberating through raw material sourcing, manufacturing logistics, and clinical procurement. Increased import levies on certain precursors and finished formulations elevated input cost considerations for manufacturers, prompting reassessments of supplier portfolios and contractual terms. In response, many stakeholders accelerated diversification strategies that prioritized regional sourcing and qualified alternate suppliers to mitigate exposure to tariff-driven costs.

These trade policy shifts also affected distribution economics and inventory strategies for hospitals, clinics, and home healthcare providers, who faced amplified scrutiny of procurement spend and inventory turn. In turn, manufacturers and distributors revisited pricing, contractual rebates, and rebate timing to preserve access while managing margin pressure. Importantly, regulatory authorities and industry associations emphasized compliance and transparency around cost pass-through to ensure continued patient access to critical therapies. The net effect underscores a heightened need for resilient supply chain design, proactive regulatory engagement, and commercial agility to navigate evolving trade and tariff environments without compromising clinical continuity.

A multi-dimensional segmentation analysis clarifying therapeutic categories, delivery pathways, clinical applications, and end-user deployment implications for strategy

A nuanced segmentation framework reveals where therapeutic development and clinical deployment diverge and converge, providing practical lenses for strategic prioritization. When parsed by opioid types, distinctions emerge between natural opiates such as codeine and morphine, semi-synthetic agents exemplified by hydrocodone and oxycodone, and fully synthetic compounds including fentanyl and methadone, each category carrying distinct pharmacology, regulatory controls, and clinical use cases that influence formulation and monitoring requirements.

Equally informative is segmentation by mode of administration, which contrasts oral routes-implemented in capsules and tablets-with parenteral options that require intramuscular or intravenous delivery, and with transdermal systems designed for sustained release. These administration pathways create divergent requirements for dosing accuracy, abuse deterrence, and device compatibility. Application-focused segmentation differentiates anesthesia applications, both general and regional, from indications like cough suppression and pain management, where acute and chronic pain profiles demand tailored therapeutic strategies and monitoring. Finally, end-user segmentation highlights deployment environments spanning healthcare facilities, where clinics and hospitals each present different formularies and utilization patterns, home healthcare settings that prioritize portability and safety, and research institutes that drive clinical innovation and early-stage evaluation. Together, these segmentation lenses support targeted product development, differentiated commercial strategies, and informed clinical policy design.

How divergent regulatory regimes, healthcare infrastructures, and payer priorities across global regions shape tailored strategies for opioid product development and access

Regional dynamics shape both clinical practice and commercial pathways, with discernible differences that affect prioritization and execution. In the Americas, clinical guidelines and payer frameworks emphasize stewardship while enabling continued access to essential analgesics across acute care settings; this creates a climate where risk mitigation strategies and real-world evidence collection are particularly salient. Meanwhile, in Europe, Middle East & Africa, regulatory heterogeneity and diverse reimbursement models create differentiated adoption curves for new formulations and abuse-deterrent technologies, necessitating tailored market-entry and regulatory strategies.

Across Asia-Pacific, rapid modernization of healthcare infrastructure and expanding clinical research capacity have catalyzed interest in novel delivery systems and localized manufacturing partnerships. The synthesis of these regional patterns suggests that successful strategies will blend global evidence generation with region-specific regulatory engagement and supply chain redundancy. Moreover, cross-regional learning, where best practices in stewardship and device integration migrate between geographies, will further influence how therapies are adopted and optimized at the point of care.

Company-level strategic responses reveal converging priorities on safety innovation, integrated manufacturing, and evidence generation to sustain clinical access

Key companies within the opioid therapeutics ecosystem demonstrate varied strategic responses that offer instructive lessons for competitors and collaborators. Industry leaders are investing in formulation technologies that reduce abuse potential and improve safety monitoring while simultaneously expanding capabilities in sterile manufacturing and controlled-substance logistics. A subset of organizations is pursuing partnerships with device manufacturers to couple pharmacology with delivery solutions that enhance dosing precision and patient adherence.

In parallel, several established firms are reallocating resources toward post-market evidence generation and pharmacovigilance systems to support regulatory filings and payer negotiations. Smaller, innovation-focused companies commonly concentrate on niche clinical applications or novel chemical entities that address unmet needs in anesthesia or chronic pain, while contract development and manufacturing organizations serve as critical enablers by providing specialized capabilities for controlled-substance production. Collectively, these company-level strategies underscore the primacy of safety innovation, regulatory collaboration, and integrated supply chain competencies.

Practical strategic priorities for leaders focused on safety-driven innovation, supply chain resilience, and collaborative stewardship to protect access and value

Industry leaders must adopt a set of actionable steps that translate insights into defensible advantage while maintaining patient safety and regulatory compliance. First, prioritize development and deployment of abuse-deterrent and safety-enhanced formulations alongside robust pharmacovigilance frameworks that generate timely real-world evidence to support clinical and payer dialogues. Second, invest in supply chain resilience through supplier diversification, strategic stock buffering, and qualification of regional manufacturing partners to reduce exposure to trade and tariff volatility.

Third, coordinate cross-functional engagement among clinical leaders, formulary committees, and payer representatives to design stewardship programs that align clinical outcomes with responsible prescribing. Fourth, pursue technology partnerships that integrate drug-device combinations and digital adherence tools to differentiate therapeutic offerings and improve patient monitoring. Finally, maintain proactive regulatory engagement and transparent communication with public health stakeholders to accelerate approvals and sustain access while demonstrating commitment to mitigating misuse and adverse outcomes. These combined actions will strengthen competitive positioning and uphold clinical responsibility.

A rigorous mixed-methods approach combining evidence synthesis, stakeholder interviews, and scenario analysis to produce defensible strategic conclusions and recommendations

The research methodology underpinning this analysis integrates systematic review of peer-reviewed clinical literature, regulatory filings, and public policy documents with structured interviews conducted across clinical, manufacturing, and regulatory stakeholders. Data collection prioritized sources that document therapeutic performance, safety profiles, and policy shifts, and synthesis emphasized triangulation among diverse evidence streams to strengthen inference validity. Qualitative interviews were designed to capture operational perspectives on supply chains, formulation challenges, and adoption barriers, enabling the report to connect strategic themes with on-the-ground realities.

Analytical approaches included thematic coding of stakeholder interviews, comparative assessment of regulatory frameworks, and scenario-based evaluation of trade and procurement impacts. Throughout, the methodology emphasized transparency in source attribution and reproducibility in analytic steps, allowing practitioners to trace conclusions back to primary evidence. Where appropriate, sensitivity analyses were conducted to test robustness of narrative conclusions against alternative policy or supply chain scenarios, ensuring that recommendations remain actionable across plausible futures.

Converging imperatives for clinical safety, commercial resilience, and collaborative stewardship to sustain access and innovation in opioid therapeutics

In conclusion, the opioid therapeutics sector is at an inflection point that demands concerted attention to safety innovation, supply chain robustness, and cross-sector collaboration. Transformations in formulation science and delivery technologies present opportunities to improve therapeutic outcomes while regulatory and trade developments impose new constraints that require adaptive commercial and operational strategies. By integrating evidence generation with stewardship programs and resilient sourcing practices, stakeholders can preserve clinical access while advancing public health objectives.

Moving forward, success will depend on organizations that align product development with demonstrable safety advantages, cultivate regional manufacturing and distribution flexibility, and invest in partnerships that enhance monitoring and adherence. The recommendations presented herein offer a pathway to reconcile clinical necessity with societal expectations, enabling responsible stewardship and sustained access to essential therapies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Surge in telemedicine-based medication-assisted treatment for opioid use disorder
  • 5.2. Widespread integration of AI-driven prescription drug monitoring programs to prevent misuse
  • 5.3. Accelerated launch of generic opioid analgesics following landmark patent expirations
  • 5.4. Growing adoption of abuse-deterrent formulations with novel polymer matrix technologies
  • 5.5. Expansion of community pharmacy naloxone distribution through state standing orders
  • 5.6. Rising collaborations between payers and providers on value-based opioid treatment contracts
  • 5.7. Intensified regulatory scrutiny on illicit synthetic opioid analogues like fentanyl and carfentanil
  • 5.8. Shift towards non-opioid pain management alternatives including CGRP and TRPV1 inhibitors
  • 5.9. Enhanced real-world evidence studies demonstrating cost effectiveness of MOUD programs
  • 5.10. Emerging legal challenges around opioid litigation settlements and fund allocation transparency

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Opioids Market, by Opioid Types

  • 8.1. Natural Opiates
    • 8.1.1. Codeine
    • 8.1.2. Morphine
  • 8.2. Semi-Synthetic Opioids
    • 8.2.1. Hydrocodone
    • 8.2.2. Oxycodone
  • 8.3. Synthetic Opioids
    • 8.3.1. Fentanyl
    • 8.3.2. Methadone

9. Opioids Market, by Mode of Administration

  • 9.1. Oral Administration
    • 9.1.1. Capsules
    • 9.1.2. Tablets
  • 9.2. Parenteral Administration
    • 9.2.1. Intramuscular
    • 9.2.2. Intravenous
  • 9.3. Transdermal Administration

10. Opioids Market, by Application

  • 10.1. Anesthesia
    • 10.1.1. General Anesthesia
    • 10.1.2. Regional Anesthesia
  • 10.2. Cough Suppression
  • 10.3. Pain Management
    • 10.3.1. Acute Pain
    • 10.3.2. Chronic Pain

11. Opioids Market, by End-User

  • 11.1. Healthcare Facilities
    • 11.1.1. Clinics
    • 11.1.2. Hospitals
  • 11.2. Home Healthcare
  • 11.3. Research Institutes

12. Opioids Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Opioids Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Opioids Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Hikma Pharmaceuticals PLC
    • 15.3.2. Pfizer Inc.
    • 15.3.3. AbbVie Inc.
    • 15.3.4. Alvogen
    • 15.3.5. Apotex Inc.
    • 15.3.6. Biesterfeld SE
    • 15.3.7. Daiichi Sankyo Company, Limited
    • 15.3.8. Elite Pharmaceuticals, Inc.
    • 15.3.9. Endo International plc
    • 15.3.10. Fresenius SE & Co. KGaA
    • 15.3.11. Humanwell Healthcare (Group) Co., Ltd.
    • 15.3.12. Indivior PLC
    • 15.3.13. Johnson & Johnson Services, Inc.
    • 15.3.14. Johnson Matthey Group
    • 15.3.15. Kyowa Hakko Kirin Co. Ltd.
    • 15.3.16. Mallinckrodt plc
    • 15.3.17. Nutriband Inc.
    • 15.3.18. Piramal Pharma Limited
    • 15.3.19. Purdue Pharma L.P.
    • 15.3.20. QuVa Pharma, Inc
    • 15.3.21. SCA Pharma
    • 15.3.22. Spectrum Chemical Mfg. Corp.
    • 15.3.23. Teva Pharmaceutical Industries Ltd.
    • 15.3.24. Tofigh Daru Research & Engineering Company
    • 15.3.25. Verve HumanCare Laboratories
    • 15.3.26. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL OPIOIDS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL OPIOIDS MARKET SIZE, BY OPIOID TYPES, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL OPIOIDS MARKET SIZE, BY OPIOID TYPES, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL OPIOIDS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL OPIOIDS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL OPIOIDS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL OPIOIDS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL OPIOIDS MARKET SIZE, BY END-USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL OPIOIDS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL OPIOIDS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS OPIOIDS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA OPIOIDS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA OPIOIDS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE OPIOIDS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST OPIOIDS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA OPIOIDS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC OPIOIDS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL OPIOIDS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN OPIOIDS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC OPIOIDS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION OPIOIDS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS OPIOIDS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 OPIOIDS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO OPIOIDS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL OPIOIDS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. OPIOIDS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. OPIOIDS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. OPIOIDS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL OPIOIDS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL OPIOIDS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL OPIOIDS MARKET SIZE, BY OPIOID TYPES, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL OPIOIDS MARKET SIZE, BY OPIOID TYPES, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL OPIOIDS MARKET SIZE, BY NATURAL OPIATES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL OPIOIDS MARKET SIZE, BY NATURAL OPIATES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL OPIOIDS MARKET SIZE, BY NATURAL OPIATES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL OPIOIDS MARKET SIZE, BY NATURAL OPIATES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL OPIOIDS MARKET SIZE, BY NATURAL OPIATES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL OPIOIDS MARKET SIZE, BY NATURAL OPIATES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL OPIOIDS MARKET SIZE, BY NATURAL OPIATES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL OPIOIDS MARKET SIZE, BY NATURAL OPIATES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL OPIOIDS MARKET SIZE, BY CODEINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL OPIOIDS MARKET SIZE, BY CODEINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL OPIOIDS MARKET SIZE, BY CODEINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL OPIOIDS MARKET SIZE, BY CODEINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL OPIOIDS MARKET SIZE, BY CODEINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL OPIOIDS MARKET SIZE, BY CODEINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL OPIOIDS MARKET SIZE, BY MORPHINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL OPIOIDS MARKET SIZE, BY MORPHINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL OPIOIDS MARKET SIZE, BY MORPHINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL OPIOIDS MARKET SIZE, BY MORPHINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL OPIOIDS MARKET SIZE, BY MORPHINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL OPIOIDS MARKET SIZE, BY MORPHINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL OPIOIDS MARKET SIZE, BY SEMI-SYNTHETIC OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL OPIOIDS MARKET SIZE, BY SEMI-SYNTHETIC OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL OPIOIDS MARKET SIZE, BY SEMI-SYNTHETIC OPIOIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL OPIOIDS MARKET SIZE, BY SEMI-SYNTHETIC OPIOIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL OPIOIDS MARKET SIZE, BY SEMI-SYNTHETIC OPIOIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL OPIOIDS MARKET SIZE, BY SEMI-SYNTHETIC OPIOIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL OPIOIDS MARKET SIZE, BY SEMI-SYNTHETIC OPIOIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL OPIOIDS MARKET SIZE, BY SEMI-SYNTHETIC OPIOIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL OPIOIDS MARKET SIZE, BY HYDROCODONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL OPIOIDS MARKET SIZE, BY HYDROCODONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL OPIOIDS MARKET SIZE, BY HYDROCODONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL OPIOIDS MARKET SIZE, BY HYDROCODONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL OPIOIDS MARKET SIZE, BY HYDROCODONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL OPIOIDS MARKET SIZE, BY HYDROCODONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL OPIOIDS MARKET SIZE, BY OXYCODONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL OPIOIDS MARKET SIZE, BY OXYCODONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL OPIOIDS MARKET SIZE, BY OXYCODONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL OPIOIDS MARKET SIZE, BY OXYCODONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL OPIOIDS MARKET SIZE, BY OXYCODONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL OPIOIDS MARKET SIZE, BY OXYCODONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL OPIOIDS MARKET SIZE, BY SYNTHETIC OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL OPIOIDS MARKET SIZE, BY SYNTHETIC OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL OPIOIDS MARKET SIZE, BY SYNTHETIC OPIOIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL OPIOIDS MARKET SIZE, BY SYNTHETIC OPIOIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL OPIOIDS MARKET SIZE, BY SYNTHETIC OPIOIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL OPIOIDS MARKET SIZE, BY SYNTHETIC OPIOIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL OPIOIDS MARKET SIZE, BY SYNTHETIC OPIOIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL OPIOIDS MARKET SIZE, BY SYNTHETIC OPIOIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL OPIOIDS MARKET SIZE, BY FENTANYL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL OPIOIDS MARKET SIZE, BY FENTANYL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL OPIOIDS MARKET SIZE, BY FENTANYL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL OPIOIDS MARKET SIZE, BY FENTANYL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL OPIOIDS MARKET SIZE, BY FENTANYL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL OPIOIDS MARKET SIZE, BY FENTANYL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL OPIOIDS MARKET SIZE, BY METHADONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL OPIOIDS MARKET SIZE, BY METHADONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL OPIOIDS MARKET SIZE, BY METHADONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL OPIOIDS MARKET SIZE, BY METHADONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL OPIOIDS MARKET SIZE, BY METHADONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL OPIOIDS MARKET SIZE, BY METHADONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL OPIOIDS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL OPIOIDS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL OPIOIDS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL OPIOIDS MARKET SIZE, BY ORAL ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL OPIOIDS MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL OPIOIDS MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL OPIOIDS MARKET SIZE, BY ORAL ADMINISTRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL OPIOIDS MARKET SIZE, BY ORAL ADMINISTRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL OPIOIDS MARKET SIZE, BY ORAL ADMINISTRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL OPIOIDS MARKET SIZE, BY ORAL ADMINISTRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL OPIOIDS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL OPIOIDS MARKET SIZE, BY CAPSULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL OPIOIDS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL OPIOIDS MARKET SIZE, BY CAPSULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL OPIOIDS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL OPIOIDS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL OPIOIDS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL OPIOIDS MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL OPIOIDS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL OPIOIDS MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL OPIOIDS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL OPIOIDS MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL OPIOIDS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL OPIOIDS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL OPIOIDS MARKET SIZE, BY PARENTERAL ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL OPIOIDS MARKET SIZE, BY PARENTERAL ADMINISTRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL OPIOIDS MARKET SIZE, BY PARENTERAL ADMINISTRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL OPIOIDS MARKET SIZE, BY PARENTERAL ADMINISTRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL OPIOIDS MARKET SIZE, BY PARENTERAL ADMINISTRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL OPIOIDS MARKET SIZE, BY PARENTERAL ADMINISTRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL OPIOIDS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL OPIOIDS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL OPIOIDS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL OPIOIDS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL OPIOIDS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL OPIOIDS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL OPIOIDS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL OPIOIDS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL OPIOIDS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL OPIOIDS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL OPIOIDS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL OPIOIDS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL OPIOIDS MARKET SIZE, BY TRANSDERMAL ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL OPIOIDS MARKET SIZE, BY TRANSDERMAL ADMINISTRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL OPIOIDS MARKET SIZE, BY TRANSDERMAL ADMINISTRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL OPIOIDS MARKET SIZE, BY TRANSDERMAL ADMINISTRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL OPIOIDS MARKET SIZE, BY TRANSDERMAL ADMINISTRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL OPIOIDS MARKET SIZE, BY TRANSDERMAL ADMINISTRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL OPIOIDS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL OPIOIDS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL OPIOIDS MARKET SIZE, BY ANESTHESIA, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL OPIOIDS MARKET SIZE, BY ANESTHESIA, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL OPIOIDS MARKET SIZE, BY ANESTHESIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL OPIOIDS MARKET SIZE, BY ANESTHESIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL OPIOIDS MARKET SIZE, BY ANESTHESIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL OPIOIDS MARKET SIZE, BY ANESTHESIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL OPIOIDS MARKET SIZE, BY ANESTHESIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL OPIOIDS MARKET SIZE, BY ANESTHESIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL OPIOIDS MARKET SIZE, BY GENERAL ANESTHESIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL OPIOIDS MARKET SIZE, BY GENERAL ANESTHESIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL OPIOIDS MARKET SIZE, BY GENERAL ANESTHESIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL OPIOIDS MARKET SIZE, BY GENERAL ANESTHESIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL OPIOIDS MARKET SIZE, BY GENERAL ANESTHESIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL OPIOIDS MARKET SIZE, BY GENERAL ANESTHESIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL OPIOIDS MARKET SIZE, BY REGIONAL ANESTHESIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL OPIOIDS MARKET SIZE, BY REGIONAL ANESTHESIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL OPIOIDS MARKET SIZE, BY REGIONAL ANESTHESIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL OPIOIDS MARKET SIZE, BY REGIONAL ANESTHESIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL OPIOIDS MARKET SIZE, BY REGIONAL ANESTHESIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL OPIOIDS MARKET SIZE, BY REGIONAL ANESTHESIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL OPIOIDS MARKET SIZE, BY COUGH SUPPRESSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL OPIOIDS MARKET SIZE, BY COUGH SUPPRESSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL OPIOIDS MARKET SIZE, BY COUGH SUPPRESSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL OPIOIDS MARKET SIZE, BY COUGH SUPPRESSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL OPIOIDS MARKET SIZE, BY COUGH SUPPRESSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL OPIOIDS MARKET SIZE, BY COUGH SUPPRESSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL OPIOIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL OPIOIDS MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL OPIOIDS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL OPIOIDS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL OPIOIDS MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL OPIOIDS MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL OPIOIDS MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL OPIOIDS MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL OPIOIDS MARKET SIZE, BY ACUTE PAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL OPIOIDS MARKET SIZE, BY ACUTE PAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL OPIOIDS MARKET SIZE, BY ACUTE PAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL OPIOIDS MARKET SIZE, BY ACUTE PAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL OPIOIDS MARKET SIZE, BY ACUTE PAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL OPIOIDS MARKET SIZE, BY ACUTE PAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL OPIOIDS MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL OPIOIDS MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL OPIOIDS MARKET SIZE, BY CHRONIC PAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL OPIOIDS MARKET SIZE, BY CHRONIC PAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL OPIOIDS MARKET SIZE, BY CHRONIC PAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL OPIOIDS MARKET SIZE, BY CHRONIC PAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL OPIOIDS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL OPIOIDS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL OPIOIDS MARKET SIZE, BY HEALTHCARE FACILITIES, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL OPIOIDS MARKET SIZE, BY HEALTHCARE FACILITIES, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL OPIOIDS MARKET SIZE, BY HEALTHCARE FACILITIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL OPIOIDS MARKET SIZE, BY HEALTHCARE FACILITIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL OPIOIDS MARKET SIZE, BY HEALTHCARE FACILITIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL OPIOIDS MARKET SIZE, BY HEALTHCARE FACILITIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL OPIOIDS MARKET SIZE, BY HEALTHCARE FACILITIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL OPIOIDS MARKET SIZE, BY HEALTHCARE FACILITIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL OPIOIDS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL OPIOIDS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL OPIOIDS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL OPIOIDS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL OPIOIDS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL OPIOIDS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL OPIOIDS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL OPIOIDS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL OPIOIDS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL OPIOIDS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL OPIOIDS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL OPIOIDS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL OPIOIDS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL OPIOIDS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL OPIOIDS MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL OPIOIDS MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL OPIOIDS MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL OPIOIDS MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL OPIOIDS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL OPIOIDS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL OPIOIDS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL OPIOIDS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL OPIOIDS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL OPIOIDS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL OPIOIDS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL OPIOIDS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS OPIOIDS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS OPIOIDS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS OPIOIDS MARKET SIZE, BY OPIOID TYPES, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS OPIOIDS MARKET SIZE, BY OPIOID TYPES, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS OPIOIDS MARKET SIZE, BY NATURAL OPIATES, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS OPIOIDS MARKET SIZE, BY NATURAL OPIATES, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS OPIOIDS MARKET SIZE, BY SEMI-SYNTHETIC OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS OPIOIDS MARKET SIZE, BY SEMI-SYNTHETIC OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS OPIOIDS MARKET SIZE, BY SYNTHETIC OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS OPIOIDS MARKET SIZE, BY SYNTHETIC OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS OPIOIDS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS OPIOIDS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS OPIOIDS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS OPIOIDS MARKET SIZE, BY ORAL ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS OPIOIDS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS OPIOIDS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS OPIOIDS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS OPIOIDS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS OPIOIDS MARKET SIZE, BY ANESTHESIA, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS OPIOIDS MARKET SIZE, BY ANESTHESIA, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS OPIOIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS OPIOIDS MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS OPIOIDS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS OPIOIDS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS OPIOIDS MARKET SIZE, BY HEALTHCARE FACILITIES, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS OPIOIDS MARKET SIZE, BY HEALTHCARE FACILITIES, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA OPIOIDS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA OPIOIDS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA OPIOIDS MARKET SIZE, BY OPIOID TYPES, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA OPIOIDS MARKET SIZE, BY OPIOID TYPES, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA OPIOIDS MARKET SIZE, BY NATURAL OPIATES, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA OPIOIDS MARKET SIZE, BY NATURAL OPIATES, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA OPIOIDS MARKET SIZE, BY SEMI-SYNTHETIC OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA OPIOIDS MARKET SIZE, BY SEMI-SYNTHETIC OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA OPIOIDS MARKET SIZE, BY SYNTHETIC OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA OPIOIDS MARKET SIZE, BY SYNTHETIC OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA OPIOIDS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA OPIOIDS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA OPIOIDS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA OPIOIDS MARKET SIZE, BY ORAL ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA OPIOIDS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA OPIOIDS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA OPIOIDS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA OPIOIDS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA OPIOIDS MARKET SIZE, BY ANESTHESIA, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA OPIOIDS MARKET SIZE, BY ANESTHESIA, 2025-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA OPIOIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 246. NORTH AMERICA OPIOIDS MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA OPIOIDS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA OPIOIDS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA OPIOIDS MARKET SIZE, BY HEALTHCARE FACILITIES, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA OPIOIDS MARKET SIZE, BY HEALTHCARE FACILITIES, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA OPIOIDS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA OPIOIDS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA OPIOIDS MARKET SIZE, BY OPIOID TYPES, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA OPIOIDS MARKET SIZE, BY OPIOID TYPES, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA OPIOIDS MARKET SIZE, BY NATURAL OPIATES, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA OPIOIDS MARKET SIZE, BY NATURAL OPIATES, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA OPIOIDS MARKET SIZE, BY SEMI-SYNTHETIC OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA OPIOIDS MARKET SIZE, BY SEMI-SYNTHETIC OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA OPIOIDS MARKET SIZE, BY SYNTHETIC OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA OPIOIDS MARKET SIZE, BY SYNTHETIC OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA OPIOIDS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 262. LATIN AMERICA OPIOIDS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA OPIOIDS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA OPIOIDS MARKET SIZE, BY ORAL ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA OPIOIDS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 266. LATIN AMERICA OPIOIDS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA OPIOIDS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 268. LATIN AMERICA OPIOIDS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA OPIOIDS MARKET SIZE, BY ANESTHESIA, 2018-2024 (USD MILLION)
  • TABLE 270. LATIN AMERICA OPIOIDS MARKET SIZE, BY ANESTHESIA, 2025-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA OPIOIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 272. LATIN AMERICA OPIOIDS MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA OPIOIDS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 274. LATIN AMERICA OPIOIDS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA OPIOIDS MARKET SIZE, BY HEALTHCARE FACILITIES, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA OPIOIDS MARKET SIZE, BY HEALTHCARE FACILITIES, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY OPIOID TYPES, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY OPIOID TYPES, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY NATURAL OPIATES, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY NATURAL OPIATES, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY SEMI-SYNTHETIC OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY SEMI-SYNTHETIC OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY SYNTHETIC OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY SYNTHETIC OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY ORAL ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY ANESTHESIA, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY ANESTHESIA, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY HEALTHCARE FACILITIES, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY HEALTHCARE FACILITIES, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE OPIOIDS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE OPIOIDS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPE OPIOIDS MARKET SIZE, BY OPIOID TYPES, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPE OPIOIDS MARKET SIZE, BY OPIOID TYPES, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPE OPIOIDS MARKET SIZE, BY NATURAL OPIATES, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPE OPIOIDS MARKET SIZE, BY NATURAL OPIATES, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPE OPIOIDS MARKET SIZE, BY SEMI-SYNTHETIC OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPE OPIOIDS MARKET SIZE, BY SEMI-SYNTHETIC OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 311. EUROPE OPIOIDS MARKET SIZE, BY SYNTHETIC OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 312. EUROPE OPIOIDS MARKET SIZE, BY SYNTHETIC OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 313. EUROPE OPIOIDS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 314. EUROPE OPIOIDS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 315. EUROPE OPIOIDS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 316. EUROPE OPIOIDS MARKET SIZE, BY ORAL ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 317. EUROPE OPIOIDS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 318. EUROPE OPIOIDS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 319. EUROPE OPIOIDS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 320. EUROPE OPIOIDS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 321. EUROPE OPIOIDS MARKET SIZE, BY ANESTHESIA, 2018-2024 (USD MILLION)
  • TABLE 322. EUROPE OPIOIDS MARKET SIZE, BY ANESTHESIA, 2025-2032 (USD MILLION)
  • TABLE 323. EUROPE OPIOIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 324. EUROPE OPIOIDS MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 325. EUROPE OPIOIDS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 326. EUROPE OPIOIDS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 327. EUROPE OPIOIDS MARKET SIZE, BY HEALTHCARE FACILITIES, 2018-2024 (USD MILLION)
  • TABLE 328. EUROPE OPIOIDS MARKET SIZE, BY HEALTHCARE FACILITIES, 2025-2032 (USD MILLION)
  • TABLE 329. MIDDLE EAST OPIOIDS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 330. MIDDLE EAST OPIOIDS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 331. MIDDLE EAST OPIOIDS MARKET SIZE, BY OPIOID TYPES, 2018-2024 (USD MILLION)
  • TABLE 332. MIDDLE EAST OPIOIDS MARKET SIZE, BY OPIOID TYPES, 2025-2032 (USD MILLION)
  • TABLE 333. MIDDLE EAST OPIOIDS MARKET SIZE, BY NATURAL OPIATES, 2018-2024 (USD MILLION)
  • TABLE 334. MIDDLE EAST OPIOIDS MARKET SIZE, BY NATURAL OPIATES, 2025-2032 (USD MILLION)
  • TABLE 335. MIDDLE EAST OPIOIDS MARKET SIZE, BY SEMI-SYNTHETIC OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 336. MIDDLE EAST OPIOIDS MARKET SIZE, BY SEMI-SYNTHETIC OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 337. MIDDLE EAST OPIOIDS MARKET SIZE, BY SYNTHETIC OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 338. MIDDLE EAST OPIOIDS MARKET SIZE, BY SYNTHETIC OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 339. MIDDLE EAST OPIOIDS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 340. MIDDLE EAST OPIOIDS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 341. MIDDLE EAST OPIOIDS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 342. MIDDLE EAST OPIOIDS MARKET SIZE, BY ORAL ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 343. MIDDLE EAST OPIOIDS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 344. MIDDLE EAST OPIOIDS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 345. MIDDLE EAST OPIOIDS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 346. MIDDLE EAST OPIOIDS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 347. MIDDLE EAST OPIOIDS MARKET SIZE, BY ANESTHESIA, 2018-2024 (USD MILLION)
  • TABLE 348. MIDDLE EAST OPIOIDS MARKET SIZE, BY ANESTHESIA, 2025-2032 (USD MILLION)
  • TABLE 349. MIDDLE EAST OPIOIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 350. MIDDLE EAST OPIOIDS MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 351. MIDDLE EAST OPIOIDS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 352. MIDDLE EAST OPIOIDS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 353. MIDDLE EAST OPIOIDS MARKET SIZE, BY HEALTHCARE FACILITIES, 2018-2024 (USD MILLION)
  • TABLE 354. MIDDLE EAST OPIOIDS MARKET SIZE, BY HEALTHCARE FACILITIES, 2025-2032 (USD MILLION)
  • TABLE 355. AFRICA OPIOIDS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 356. AFRICA OPIOIDS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 357. AFRICA OPIOIDS MARKET SIZE, BY OPIOID TYPES, 2018-2024 (USD MILLION)
  • TABLE 358. AFRICA OPIOIDS MARKET SIZE, BY OPIOID TYPES, 2025-2032 (USD MILLION)
  • TABLE 359. AFRICA OPIOIDS MARKET SIZE, BY NATURAL OPIATES, 2018-2024 (USD MILLION)
  • TABLE 360. AFRICA OPIOIDS MARKET SIZE, BY NATURAL OPIATES, 2025-2032 (USD MILLION)
  • TABLE 361. AFRICA OPIOIDS MARKET SIZE, BY SEMI-SYNTHETIC OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 362. AFRICA OPIOIDS MARKET SIZE, BY SEMI-SYNTHETIC OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 363. AFRICA OPIOIDS MARKET S